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7ABSTRACT
Hearing disorders are among the top 10 in terms of burden of 
disease in middle- and high-income countries, affecting 250 million 
people worldwide. During the last few decades researchers have 
made significant advances in understanding the basic mechanisms 
and molecular biology of inner ear diseases. The principal challenge 
in treatment of the inner ear is that the targets for pharmacological 
therapy are inaccessible due to the various barrier systems of the 
inner ear, and that the inner ear is embedded in the base of the skull. 
New technologies to provide safe and efficacious delivery of drugs 
to the inner ear are of great clinical interest. Local administration 
of medication to the inner ear would solve some of the problems 
associated with systemic delivery, such as drug interaction and 
systemic side effects. The aim of the research presented in this 
thesis was to elucidate different aspects of drug delivery to the 
inner ear using a local application technique.
The round window membrane (RWM) is believed to be the 
main route for drug delivery to the inner ear when a drug is 
administered to the middle ear i.e. by an intratympanic injection. 
A morphological study of the round window performed on 
cynomolgus monkey described in Paper I showed the existence 
of a local defense system housed within the rim of the RWM. 
Previously undescribed gland-like structures were identified in the 
loose connective tissue of the mucosal layer near the bony insertion 
of the RWM. These findings could explain why labyrinthitis is 
rare despite the close proximity of the infection-prone middle 
ear. A local immunodefense system would also most likely affect 
the transport of drugs from the middle ear cavity to the inner ear 
and needs to be taken into consideration when developing new 
strategies for local drug administration in the middle ear.
In the studies on which Paper II is based, the rheological and 
safety aspects of three candidate vehicles for intratympanic drug 
administration were investigated. The results speak in favor of 
sodium hyaluronate (HYA gel) which, in contrast to carboxymethyl 
cellulose and poloxamer 407, did not cause lasting or significant 
increases in hearing threshold after intratympanic injection in 
8the guinea pig. Studies of vehicle elimination and morphological 
investigations support HYA gel as the most promising candidate 
for intratympanic administration.
An important factor for local administration of drugs to the 
middle ear aimed for inner ear treatment is the adherence of the 
vehicle to the RWM. The distribution and elimination of HYA 
gel after intratympanic injection to the auditory bulla in guinea 
pig were investigated by magnetic resonance imaging in Paper 
III. HYA gel was distributed in a predictable way and filled the 
middle ear cavity well. The HYA gel remained close to the RWM 
for more than 24 hours. A myringotomy was needed before 
middle ear administration to allow air to escape and prevent 
trauma to the RWM. 
The hypothesis that higher concentrations of a drug in the 
inner ear could be achieved by local administration than through 
systemic administration was investigated in Paper IV and V using 
the antioxidant thiosulfate, which has previously been identified 
as a promising otoprotector against cisplatin-induced ototoxicity. 
The concentration of thiosulfate in scala tympani perilymph was 
much higher after intratympanic delivery to the guinea pig using 
an injection of a thiosulfate-containing HYA gel than after i.v. 
administration of a thiosulfate solution. The levels of thiosulfate 
in blood remained low after intratympanic administration, 
confirming that this delivery system will not risk decreased 
antitumoral effect due to cisplatin inactivation in tumor tissue.
The final study, Paper V, demonstrated that ototoxicity in 
guinea pigs treated with the antineoplastic drug cisplatin was 
reduced by injection of thiosulfate-containing HYA gel three 
hours prior to the systemic cisplatin injection. This confirms 
the hypothesis of thiosulfate being a promising otoprotector for 
cisplatin induced hearing loss and also shows that drugs can be 
delivered locally to the inner ear by intratympanic injection using 
HYA gel as a vehicle.
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ABBREVIATIONS
ABR auditory brainstem response
BM basilar membrane
CSF cerebrospinal fluid
EP endocochlear potential
Gd-DTPA-BMA gadolinium-diethylenetriamine pentaacetic 
acid-bis methylamine
HYA gel sodium hyaluronan (0.5% w/w)
IHC inner hair cell
ISSNHL idiopathic sudden sensorineural hearing loss 
MHC monohydrated cisplatin complex
MRI magnetic resonance imaging
NaCMC sodium carboxymethyl cellulose (0.5% w/w)
NaHYA sodium hyaluronan (0.5% w/w)
OHC outer hair cell
PLGA poly lactic co-glycolic acid
POL poloxamer 407 (25% w/w)
ROS reactive oxygen species
RWM round window membrane
SM scala media
SNHL sensorineural hearing loss
ST scala tympani
SV scala vestibuli
TM tympanic membrane
WHO World Health Organization
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INTRODUCTION
The present thesis is based on a project with the ultimate goal of 
developing a model for pharmacological treatment of inner ear 
disorders by administration of a drug-loaded vehicle to the middle 
ear cavity. 
Ear and hearing
The ear can be divided anatomically into three regions: the 
external ear, the middle ear and the inner ear. Functionally it is 
divided into two parts where the external and the middle ear form 
the conduction part and the inner ear the perception part. 
External ear
The external ear consists of the auricle, the external auditory canal 
and the tympanic membrane (TM) (Figure 1). The fibroelastic 
cartilage of the auricle is covered with skin. In humans the outer 
hearing canal is about 3 cm long and S-shaped. The lateral part of 
the external auditory canal is composed of cartilage covered with 
skin that contains hair follicles and cerumen-producing sebaceous 
glands whereas the medial part, located in the temporal bone, is 
Figure 1. Anatomy of the human ear.
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lined by skin without hair follicles and glands. 
The primary function of the external ear is to act as a resonator 
and guide the pressure oscillations of sound to the TM, setting it 
into vibration.
The middle ear
The middle ear is an air-filled space also called the tympanic cavity 
(Figure 1). It is limited laterally by the TM and medially by the 
cochlear eminence. The Eustachian tube (Figure 1) connects the 
middle ear with the rest of the upper airways. The tympanic cavity 
harbors the three ossicules named the malleus, the incus and the 
stapes (Figure 1). They are connected as a chain running from the 
superior part of the TM, where the long process of the malleus is 
attached, via the incus to the stapes. The footplate of the stapes is 
attached to the cochlea at the oval window by the stapedo-vestibular 
joint. The middle ear epithelium is part of the respiratory mucosa 
and is lined by a single layer of flat or cuboidal epithelial cells. 
Sound waves cause pressure oscillations in the air-filled middle 
ear, which are transferred to fluid in the inner ear. The different 
densities of air and liquid, i.e. the different impedances of the 
media, limit the transfer of sound energy from the air to the inner 
ear fluid. However, the leverage function of the ossicules and the 
fact the air interface (TM) is approximately 20 times larger than 
the fluid interface at the oval window (Figure 1) contribute to 
impedance matching and thus to the still comparatively efficient 
transmission of sound energy in the middle ear. This impedance 
matching is most effective when the pressure in the middle ear is 
equal to that of the environment. Middle ear pressure is normally 
adjusted to the varying air pressure of the environment by brief 
opening of the Eustachian tube during yawning or swallowing.
The inner ear
The inner ear consists of the cochlea (Figure 1) dedicated to 
hearing, and the vestibular system with its semicircular canals 
(Figure 1), utricle and saccule dedicated to balance. It is embedded 
and protected deep within the petrous part of the temporal bone. 
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The cochlea (Figure 2) has the shape of a coiled shell. Its length 
varies and the number of turns ranges from two to four depending 
on species. However the size of the mammalian cochlea is not 
proportional to the size of the species. The human cochlea is 
approximately 32 mm long with two and a half turns and in the 
guinea pig the length is approximately 11 mm with three and a 
half turns (Wysocki, 2005; Wysocki, 2008). The cochlea consists of 
three fluid-filled compartments: the scala vestibuli (SV), the scala 
tympani (ST) and the scala media (SM) (Figure 2). These scalae 
wind side by side around the central body axis of the cochlea, 
the modiolus, that contains the spiral ganglion and the cochlear 
nerve. At the apical end of the cochlea SV and ST merge in the 
helicotrema. These two scalae are filled with perilymph, a sodium-
rich fluid with an ionic composition similar to that of extracellular 
Figure 2. Schematic drawing of the human cochlear anatomy. Top right corner: 
mid-modiolar section of the cochlea. The left figure illustrates the spiral canal of 
the cochlea divided into three membranous ducts (scala vestibuli, scala media 
and scala tympani, which wind around the modiolus to the apex of the cochlea). 
The Organ of Corti is situated in the scala media containing the inner and outer 
hair cells (IHC and OHC) (bottom right corner). 
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fluid whereas SM is filled with endolymph which is comparable 
to intracellular fluid, rich in potassium and low in sodium (Smith 
et al., 1954). There is a large positive electro-chemical potential 
difference between the endolymph and perilymph with the 
positive endocochlear potential (EP) in the SM maintained by the 
stria vascularis (Figure 2) in the radial border of SM (Patuzzi, 2011). 
SM is separated from SV and ST by Reissner’s membrane (Figure 
2) and the basilar membrane (BM) (Figure 2) respectively. On the 
BM lies the actual hearing organ, the Organ of Corti, with the 
inner and outer hair cells (IHCs and OHCs respectively) (Figure 
2). The hair cells are organized into one row of IHCs and three 
rows of OHCs. In humans, each cochlea has about 3000 IHCs 
and 12000 OHCs (Ulehlova et al., 1987) and in the guinea pig 
there are about1900 IHCs and 6600 OHCs (Fransson A., personal 
communication). The cochlear hair cells have stereocilia on their 
apical surface which project towards and are partly embedded in 
the tectorial membrane.
From a pharmacological point of view the inner ear can be 
considered as a three-compartment model, the perilymphatic, the 
endolymphatic and the sensory tissue compartments.
Besides the oval window, which is covered by the foot-plate 
of the stapes and is located at the bony enclosure of the SV, the 
cochlea has another opening called the round window (Figure 
1). This window is at ST and is covered by the round window 
membrane that separates the inner ear from the middle ear.
When acoustic stimulation of the ear reaches the stapes at the 
oval window, the vibrations cause a pressure difference between 
SV and ST that will set the BM in movement. The BM is rigid at 
the base of the cochlea and more flexible at the apical part; this 
means that a specific frequency will elicit maximum oscillation 
in a specific region of BM. High frequencies evoke the largest 
vibration amplitude at the base of the cochlea and low frequencies 
at the apex. The movement of the basilar membrane creates a 
shear force relative to the parallel sheet of the tectorial membrane, 
thus causing deflection of the stereocilia. As a result, ion channels 
open, the IHCs depolarize and release neurotransmitter to excite 
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afferent neurons. The nerve impulses generated by the IHCs then 
travel via the spiral ganglion cells to the auditory nerve and the 
auditory cortex. The IHCs are regarded as the primary sensory 
receptors and have a central function in hearing. The OHCs 
are believed to have dynamic micromechanical properties that 
contribute to the high sensitivity, high frequency selectivity and 
wide dynamic range of the hearing organ (Brownell et al., 1985).
Hearing disabilities
Hearing impairment is the most frequent sensory deficit in human 
populations, affecting more than 250 million people worldwide. 
According to the World Health Organization (WHO), hearing 
problems are among the top 10 most common burdens of 
disease in middle- and high-income countries (Mathers et al., 
2000; Mathers and Loncar, 2006). The results of a Swedish study 
indicate that hearing loss and tinnitus affect more than 30% of 
the Swedish population (Hasson et al., 2010). Approximately 
every fifth young adult (under 40 years of age) in Sweden has 
either tinnitus or hearing loss, indicating that hearing problems 
may be even more common in the future (Hasson et al., 2010). 
The prevalence of hearing loss and tinnitus is age-related but also 
influenced by cumulative exposure to noise (Henry et al., 2005; 
Nelson et al., 2005). Men are more often affected than women 
(Agrawal et al., 2008). 
Hearing losses can be divided into two main types, conductive 
and sensorineural. Conductive hearing loss is caused by 
abnormalities or obstruction of the outer and middle ear that 
hamper the sound on its way to the cochlea. Among the various 
causes of conductive hearing loss are inflammation, or congenital 
malformation, of the outer or middle ear. Conductive hearing 
loss can often be treated surgically, medically or with hearing 
aids. Sensorineural hearing loss (SNHL) is classified either 
as a cochlear hearing loss, when the hearing loss is caused by 
abnormalities of the cochlea, or as a retrocochlear hearing loss, 
when the abnormalities are located in the auditory nerve or the 
auditory centers at the brainstem or the cortex of the brain. The 
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cochlea is the most frequently affected site among people with 
hearing disabilities of the sensorineural type. The causes of SNHL 
include heritable diseases, noise exposure, autoimmune disease, 
meningitis, head trauma, tumors, and ototoxic lesions; age-related 
factors also play a role. A person with SNHL may not only have a 
reduced ability to hear faint sounds but often also problems with 
tinnitus, difficulties interpreting speech in noisy surroundings, and 
hyperacusis. Humans and other mammals have no ability to restore 
damaged inner and outer hair cells or neurons and there is to date 
no cure for SNHL. Functional improvement can be achieved with 
hearing aids that work as amplification devices and with cochlear 
implants that stimulate auditory neurons electrically. New drugs 
and innovative drug delivery systems are being developed to treat 
various inner ear ailments such as ototoxicity, autoimmune inner 
ear disease, idiopathic sudden sensorineural hearing loss (ISSNHL) 
and for regenerating sensory cells and preserving neurons. Progress 
in the field of inner ear drug delivery would ultimately lead to 
improved quality of life for the large group of patients suffering 
from hearing-related disorders.
Systemic treatment of the inner ear
Systemic administration of medications directed to the inner 
ear consists of dosing medication via the oral, intravenous or 
intramuscular route. Streptomycin was one of the first medications 
to be used for systemically treatment of inner ear disease. This 
drug had been found to be ototoxic soon after its discovery and 
as early as 1948 it was recognized that the ototoxic effect could be 
put to use as treatment to control vertigo (Fowler, 1948). The most 
common indication for streptomycin today in inner ear treatment 
is severe bilateral Ménière’s disease, for which the drug is given 
intramuscularly and titrated according to clinical effect (Berryhill 
and Graham, 2002; Sataloff et al., 1996). Another example of 
systemic treatment of inner ear disorder is systemic steroids, 
which have become a standard treatment worldwide for ISSNHL. 
However, the efficacy of this treatment has been questioned on 
the basis of methodological deficiencies and lack of well-designed 
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randomized controlled clinical trials with adequate power (Conlin 
and Parnes, 2007; Wei et al., 2006). Other drugs that have been 
delivered systemically to target the inner ear are diuretics for 
Ménière’s disease (Coelho and Lalwani, 2008), N-acetylcysteine 
for noise-induced hearing loss (Coleman et al., 2007; Kopke et 
al., 2007) and bisphosphonates for otosclerosis (Brookler, 2008). 
The literature contains very few prospective, randomized studies 
on pharmacological treatment of well-defined inner ear disorders. 
Most studies are based on a small number of patients given a 
specific drug, and lack a control group.
However, clinical use of systemically administered medications 
for treatment of inner ear disorders raises many concerns, such 
as unacceptable side-effects and drug interactions in the blood 
compartment (Ekborn et al., 2002). Moreover, it may be difficult 
for a drug to reach the inner ear from the systemic circulation due 
to various barrier systems between the blood compartment and 
inner ear compartments (Juhn, 1988; Sterkers et al., 1982). These 
disadvantages make local drug delivery attractive.
Local treatment of the inner ear
In the search for safe and effective medical treatment of the inner 
ear, various techniques have been developed that permit local drug 
delivery either to the middle ear or directly to the inner ear.
Intratympanic injection
Injection to the middle ear with a needle, through a myringotomy 
or through a tympanostomy tube is the simplest way to deliver 
medication aimed for inner ear treatment. This technique uses the 
middle ear as a reservoir for drug transport to deeper compartments. 
It is minimally invasive, quick and easy to repeat if necessary. 
Intratympanic injection can be performed in an outpatient setting 
and the technique is currently in widespread use. The level of a 
drug in perilymph after application to the middle ear is influenced 
by the drug’s ability to permeate through the round window 
membrane (RWM) and by its residence time, which is determined 
by how fast the drug is eliminated from the round window niche 
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by the middle ear mucosa and how fast the injected solution is 
drained from the middle ear through the Eustachian tube. These 
factors might explain the large variability in the results reported 
from pre-clinical and clinical trials on the effect of intratympanic 
injections. Development of a method that delivers a fixed dose 
and ensures contact with the RWM would be of great importance 
for solving the problems relating to drug delivery to the inner ear 
by intratympanic administration.
The first local drug delivery to the inner ear of humans 
was developed in the 1950s for treatment of Ménière’s disease 
with local anesthetics (Ersner et al., 1951) and antibiotics 
(Schuknecht, 1956). Today intratympanic application of 
gentamicin is a common strategy for the treatment of Ménière’s 
disease (Ghossaini and Wazen, 2006). Another method currently 
in widespread use to treat inner ear disease is intratympanic 
steroid therapy, which has been shown to be effective against 
Ménière’s disease in some studies (Boleas-Aguirre et al., 2008; 
Garduno-Anaya et al., 2005), but had yielded discouraging 
results in others (Silverstein et al., 1998). However, intratympanic 
delivery of steroids is best known for the treatment of ISSNHL 
in which context it has been used as salvage therapy after 
systemic treatment with steroids has failed (Lefebvre and 
Staecker, 2002; Slattery et al., 2005) or as combination therapy 
when a high dose of prednisone is being tapered off (Battaglia 
et al., 2008; Lautermann et al., 2005). However, none of these 
studies drew any definitive conclusions based on statistically 
significant differences between study groups, and the trials were 
not randomized. Some studies showed good outcome of locally 
administered prednisone and some did not. In order to resolve 
some of the controversy concerning therapy for ISSNHL the 
National Institute of Health sponsored a recently published 
multicenter treatment trial which concluded that intratympanic 
steroid treatment was not inferior to oral steroid treatment and 
could therefore be a suitable alternative if there are medical 
contraindications to oral steroids (Rauch et al., 2011). Other 
disorders that have been treated with intratympanic steroids are 
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autoimmune inner ear disease (Light and Silverstein, 2004) and 
tinnitus (Dodson and Sismanis, 2004).
Local application by intratympanic injection has been used 
experimentally for a variety of therapeutic agents, including 
antibiotics, steroids, anti-oxidants and neurotrophins. Efforts 
to control the variability in drug delivery to the inner ear have 
led to the development of volume stabilizing vehicles aimed for 
middle ear administration. These vehicles consist of biodegradable 
polymers or hydrogel delivery systems into which the drug can 
be loaded. The release of the drug is then dependent on the 
degradation of the material and drug diffusion from the vehicle. 
Examples of biodegradable vehicles that have been used for middle 
ear application are natural materials like hyaluronan (Borden et al., 
2011; Kelly et al., 1999; Saber et al., 2009), gelatin (Endo et al., 
2005; Ito et al., 2005) and chitosan (Paulson et al., 2008; Saber 
et al., 2010; Xu et al., 2010) and synthetic polymers such as poly 
lactic co-glycolic acid (Horie et al., 2010; Tamura et al., 2005) and 
poloxamers (Piu et al., 2011; Salt et al., 2010; Wang et al., 2009). Of 
these, only hyaluronan and poloxamers have been used as vehicles 
for application in which the middle ear has been filled. All the 
other materials have been used for middle ear administration as 
described below. One major drawback to the use of intratympanic 
injection is the transient conductive hearing loss that the patient 
experiences when the middle ear is filled with the vehicle. Another 
is the potential reaction of the middle ear mucosa to the drug or 
vehicle.
Round window administration
As the RWM is believed to be the most important interface for 
drug uptake to the inner ear after middle ear administration, 
various techniques for drug application to the round window have 
been developed. These techniques are described below and the 
properties of the round window membrane will be discussed in 
the section about drug transport to the inner ear.
The delivery system called the MicroWick is a small wick 
(1 x 9 mm) composed of polyvinyl acetate that can be inserted 
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through a tympanic membrane ventilation tube into the round 
window niche (Silverstein, 1999). The patient can then self-
administer eardrops into the ear canal, where they are absorbed 
by the wick and transported to the RWM. The MicroWick has 
successfully been used in clinical studies to deliver gentamicin in 
order to treat Ménière’s disease (Hill et al., 2006; Suryanarayanan 
et al., 2009) and to deliver methylprednisolon for ISSNHL (Van 
Wijck et al., 2007). Potential complications of treatment with 
MicroWick are infections of the middle or external ear, tissue 
ingrowth in the middle ear leading to fibrosis or cholesteatoma 
and the development of a persistent perforation of the tympanic 
membrane (Robey et al., 2010).
The implantable microcatheter method can be used to deliver 
medication continuously to the RWM. This technique involves 
implanting a microcatheter via a well in the posterior part of the 
external auditory canal and through a tunnel in the eardrum to 
the round window niche. The system makes it possible to deliver 
medication continuously for several weeks. It has been used to 
deliver steroids to the RWM in patients with ISSNHL (Herr and 
Marzo, 2005; Kopke et al., 2001; Plontke et al., 2009; Sun et al., 
2007) and gentamicin in patients with Ménière’s disease (Charabi 
et al., 2000; Hoffer et al., 2001; Suryanarayanan and Cook, 2004). 
However, this delivery system involves surgical intervention with 
its associated risks, as well as the risk of persistent perforation of the 
tympanic membrane and the risk that the patient will accidentally 
dislocate the catheter (Plontke et al., 2006). 
As mentioned above, biodegradable vehicles including 
gelatin, chitosan and poly lactic co-glycolic acid have been used 
in experimental studies for drug application to the RWM. Among 
the drugs that have been delivered to the inner ear by this method 
are brain-derived neurotrophic factor (Endo et al., 2005; Havenith 
et al., 2011), insulin-like growth factor (Fujiwara et al., 2008; Lee 
et al., 2007) and dexamethasone (Paulson et al., 2008). This drug 
delivery system ensures that the drug is in close contact with the 
RWM and the medication can be released, e.g. by hydrolysis in a 
controlled fashion or by diffusion out of the matrix. The vehicle 
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used can also be altered to change the dynamics of drug release 
(Paulson et al., 2008). The main disadvantage of this method is 
that surgical intervention is required for proper placement in the 
round window niche. Compared to the middle ear injection, where 
the entire middle ear is filled, the risk of transient conductive 
hearing loss is smaller, but on the other hand, since the volume 
applied at the round window is small, it might not contain enough 
medication for the desired treatment time. 
Nanotechnology is an expanding scientific field and is 
expected to have far-reaching effects in many fields of medicine. 
Nano-otology denotes nanomedicine as applied to diseases and 
disorders of the ear. By definition, a nanoparticle has a diameter 
of less than 1000 nm; those used for drug delivery to the inner 
ear are often 200 nm or less (Hornyak, 2005). Nanoparticles have 
been shown to reach the cochlea when administered systemically 
but the intracochlear concentration is higher when the particles 
are applied to the RWM (Tamura et al., 2005). To date, however, 
there is no published evidence of successful treatment of inner ear 
disorders using nanoparticles as drug carriers. 
Intracochlear drug delivery
Drugs delivered directly into the cochlea have higher bioavailability 
in the cochlear tissue than drugs applied topically in the middle 
ear, and also have more direct access to sensory cells and neurons. 
Intracochlear drug delivery is performed either by a cochleostomy 
through the otic capsule (typically to the ST but both SM and SV 
have been explored as routes for delivery) or by injection through 
the RWM. Technical solutions designed to deliver drugs directly to 
the inner ear consist of micro-pumps with active or passive control 
systems, alone or in combination with a cochlear implant. 
Osmotic pumps were the first intracochlear delivery system to 
be explored (Kingma et al., 1992). They operate by establishing an 
osmotic gradient that drives the drug out of a canister – and in the 
case of intracochlear delivery through a cannula into the cochlea – 
at a rate determined by the design of the device (Borenstein, 2011). 
In experimental studies for example brain-derived neurotrophic 
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factor (Agterberg et al., 2009; McGuinness and Shepherd, 2005), 
dexamethasone (Takemura et al., 2004), gentamicin (Lii et al., 
2004) and thiourea (Ekborn et al., 2003) have been delivered using 
osmotic pumps. Among the disadvantages of this method are 
that investigators cannot stop and restart the treatment without 
removing the system, cannot vary dosage and dosing intervals, 
and cannot refill the pump.
Direct injection to the cochlea has been used for gene 
transfer and delivery of liposomes and agents capable of reducing 
damage associated with cochlear implant (Oestreicher et al., 1999; 
Praetorius et al., 2007; Stover et al., 1999). Another delivery system 
is the syringe pump delivery that has been used experimentally to 
establish kinetic models for drug transport in the ST (Borkholder 
et al., 2010; Plontke et al., 2007). These two constant infusion 
approaches are, however, hindered by the low rate of clearance 
of cochlear fluids and thus the limited volume of a drug that can 
be administered during a certain time without causing injury to 
the cochlea. The cochlear scalae are relatively long and narrow 
passages and the apical part of the cochlea is difficult to reach 
with surgery. Since the cochleostomy is often made in the basal 
part of the cochlea, it is difficult getting drugs to the apical region. 
A reciprocating distribution system for intracochlear delivery has 
therefore been developed in which a volume of drug is infused and 
the same amount of perilymph is withdrawn in a cyclic manner 
without any accompanying change in fluid volume within the 
cochlea (Chen et al., 2005; Fiering et al., 2009; Pararas et al., 2011; 
Sewell et al., 2009). A recirculation component of the delivery 
device permits delivery of a drug at a constant concentration 
over an extended period of time – potentially for years – without 
any need to refill the reservoir. So far a few studies on laboratory 
animals have been performed using this new delivery system in 
order to examine drug kinetics within the cochlea. The drawbacks 
of this delivery system are associated with the surgical intervention 
needed for implantation.
A cochlear implant is a device that provides a sense of sound 
to a person who is profoundly deaf or severely hard of hearing 
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by direct stimulation of the auditory nerve. It comprises a 
microphone, speech processor, transmitter, receiver and electrode 
array. The latter is implanted into the inner ear via a cochleostomy 
or through the RWM, which makes the cochlear implant a 
pathway for drug delivery to the inner ear. Delivery systems that 
have been integrated with a cochlear implant include the use of 
biorelease polymers coated onto the implant electrodes (Dinh 
et al., 2008; Hendricks et al., 2008; Richardson et al., 2009) and 
the connection of external pump systems (Paasche et al., 2006; 
Shepherd and Xu, 2002). In experimental studies, neurotrophic 
factors aiming to preserve spiral ganglion cells (Richardson et al., 
2009) and dexamethasone (Dinh et al., 2008) have been delivered 
using this route. Side effects of modified cochlear implants for 
drug distribution to the inner ear could be greater risk of infection 
and disturbed function of the implant. 
Drug transport to the inner ear
Systemic administration
Drugs administered systemically have to pass the blood-cochlear 
barrier to reach the inner ear compartments. The blood-cochlear 
barrier is physiologically similar to the blood-brain barrier 
(Juhn and Rybak, 1981; Juhn, 1988). It consists of a continuous 
capillary endothelium lining blood vessels in the cochlea and 
these endothelial cells are connected with tight junctions (Jahnke, 
1975; Kimura and Ota, 1974). This means that drugs in the blood 
compartment have to be actively or passively transported across 
the capillary endothelia. Drug molecules that are large or highly 
charged will have greater difficulty crossing the barrier than small 
drugs with high lipid solubility. High capacity to bind to protein 
will also increase a drug’s ability to cross. The positive potential of 
SM is another obstacle to drug entry and positively charged drugs 
tend not to enter SM since the electrical gradient works against 
them (Salt et al., 1991b; Salt and DeMott, 1995). Components 
such as enzymes and cellular uptake systems within the blood-
cochlear barrier might also affect the concentration of medication 
24
that reaches the cochlea from the blood compartment, but these 
are not yet well characterized (Swan et al., 2008). 
Local administration to the middle ear 
There is experimental support that drugs can be taken up into 
the inner ear over several interfaces between the middle and the 
inner ear including the RWM, the oval window and the bony otic 
capsule.
The round window membrane
The RWM is localized in the medial wall of the middle ear within 
the round window niche at the basal end of the cochlea. In the 
human being, the RWM is approximately 70 µm thick (Carpenter 
et al., 1989) and in the guinea pig about 12 µm. It consists of three 
layers: an outer epithelium facing the middle ear cavity, a core of 
connective tissue and an inner epithelium facing the ST of the 
inner ear (Goycoolea and Lundman, 1997). The outer epithelium 
consists of a single layer of low cuboidal to flat cells on a basal 
membrane and is a continuation of the middle ear mucosa. Tight 
junctions connect the cells of the outer epithelium and the core 
contains connective tissue fibroblasts, fibrocytes, collagen, elastin, 
capillaries, and nerves (Schachern et al., 1982). The inner epithelial 
layer is a continuation of the cell lining in the ST and the cells are 
flat, squamous and overlap each other (Goycoolea, 2001). 
The basic function of the RWM is believed to be to permit 
displacements and changes of fluid pressure in the inner ear when 
the stapes footplate in the oval window is put in motion by sound 
stimulation (Goycoolea and Lundman, 1997; Wever and Lawrence, 
1948). The RWM has also been suggested as an alternative route 
for sound stimulation (Goycoolea and Lundman, 1997). Even 
though the middle ear is an area prone to infections, the spread 
of microorganisms to the inner ear is very rare. The RWM 
most probably takes part in a local defense system, undergoing 
histopathological changes when exposed to injury (Goycoolea 
and Lundman, 1997; Goycoolea, 2001). For passage of substances 
from the middle to the inner ear, the RWM is believed to be the 
most important route and may act as a semi-permeable membrane 
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(Goycoolea, 2001; Lundman, 1993). The thickness of the RWM 
affects its permeability (Goycoolea et al., 1988b). The severity and 
the duration of a middle ear inflammation affect both the thickness 
and the permeability of the RWM. Its permeability is increased 
in the early phase of otitis media, but the membrane becomes 
thicker and more impermeable at later stages of disease (Ikeda and 
Morizono, 1988; Kim et al., 1990; Lundman et al., 1992; Schachern 
et al., 1987). A substance’s passage over the RWM is dependent 
on its size, structure and electrical charge. Substances with low 
molecular weight (<1 kDa) such as sodium ions, gentamicin, 
neomycin and streptomycin pass readily through the RWM (Juhn 
et al., 1989). Substances with high molecular weight (>10 kDa) such 
as ferritin, albumin and endotoxins, on the other hand, can only 
be transported through the membrane by pinocytocis (Juhn et al., 
1989). The positively charged ferritin ion can be transported across 
the membrane (Goycoolea et al., 1988a; Goycoolea et al., 1988b) 
whereas the negatively charged ferritin ion cannot (Goycoolea et 
al., 1988b). A number of substances can increase the permeability 
of the RWM such as histamine, leukotrienes and prostaglandins 
(Juhn et al., 1989) as well as exotoxin of Staphylococcus aureus 
and endotoxin of Escherichia coli (Engel et al., 1995; Engel et 
al., 1998; Ikeda and Morizono, 1988). Drug solution osmolarity, 
benzyl alcohol content, and possible injury to the RWM during 
suctioning of the middle ear are also factors that influence the 
permeability (Mikulec et al., 2008). 
The oval window
The oval window consists of the stapes footplate and the annular 
ligament. This structure has been suggested as a secondary route 
of passage for particles from the middle ear cavity to the inner 
ear (Saijo and Kimura, 1984; Tanaka and Motomura, 1981). 
However, it is technically difficult to measure the amount entering 
the inner ear through this route. Attempts to occlude the RWM 
e.g. with dental cement (Saijo and Kimura, 1984) have not been 
fully successful. There is also a radial communication between 
the perilymphatic scalae of the cochlea (Salt et al., 1991a; Salt et 
al., 1991b), making it even more difficult to draw any conclusion 
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about drug entry through the oval window based only drug 
concentrations in the SV or the saccule. Thus the possibility of 
any drug uptake through the oval window is still uncertain but if 
it occurs, it is most probably influenced by drug size and charge. 
Even under optimal conditions, the amount of drug that can be 
taken up via this pathway is thought to be small compared to that 
entering though the RWM (Salt and Plontke, 2009).
The bony otic capsule
It has recently been shown that drugs can enter the perilymph 
through the thin bony otic capsule in the apical turns of the guinea 
pig cochlea when the drug is applied by intratympanic injection 
and the middle ear is filled with solution (Mikulec et al., 2009). In 
humans, the bone of the otic capsule is thicker than in the guinea 
pig and drugs will probably not penetrate to the same extent. This 
illustrates a considerable problem of extrapolating results from 
animal studies to human beings since drug distribution patterns 
along the length of the cochlea are likely to differ.
Drug distribution within the inner ear
Knowledge on drug distribution, or drug trafficking, within the 
inner ear is rather limited. Many of the structures in the inner 
ear are in diffusional continuity with the perilymph. A drug can 
therefore diffuse from the perilymph into the Organ of Corti, with 
its hair cells, neural terminals and other specialized supporting 
cells (Ilberg and Vosteen, 1969). Drugs might also be able to 
enter the modiolus and thus reach the spiral ganglion through 
numerous canaliculi on the surface of the osseous spiral lamina 
(Rask-Andersen et al., 2006; Schuknecht and Seifi, 1963). SV and 
ST are in direct communication via the helicotrema at the apex 
of the cochlea. The rate of longitudinal flow of perilymph in the 
cochlea is reported to be very slow, less than 2 nl/min (Ohyama 
et al., 1988), and drug distribution via this route is therefore 
limited to passive diffusion. Because of the relatively long distance 
between the basal turn of ST and the basal turn of SV transport 
via the helicotrema would be extremely slow. The possibility of a 
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radial communication has been suggested (Duvall, 1972; Konishi 
et al., 1978; Saijo and Kimura, 1984; Salt et al., 1991a; Salt et al., 
1991b) and is presumed to occur through the loose and fibrous 
intracellular spaces of the spiral ligament. 
An intracochlear barrier, the perilymph-endolymph barrier, 
restricts entry of drugs and other substances from the perilymphatic 
compartment to the endolymphatic compartment (Laurell et 
al., 1995b; Salt et al., 1991b; Salt and DeMott, 1995). The cells 
lining the endolymphatic space including the stria vascularis 
are connected through tight junctions (Jahnke, 1975) and the 
perilymph-endolymph barrier is semi-permeable or impermeable 
for substances other than water (Hirt et al., 2010; Sterkers et 
al., 1982; Sterkers et al., 1987). The entry of substances to the 
endolymph via the perilymphatic space is likely to depend on 
the electrical charge due to the endocochlear potential. Cationic 
markers have been shown to be excluded from endolymph (Salt et 
al., 1991b) whereas anionic markers are accumulated and retained 
(Salt and DeMott, 1995).
How drugs reach and are taken up by the inner and outer hair 
cells is not fully understood. Besides the perilymphatic route, an 
endolymphatic pathway and uptake of drugs through the apical 
parts of the inner and outer hair cells has been suggested (Steyger 
et al., 2003; Wang and Steyger, 2009). 
Metabolism and elimination from the inner ear
Little is known about how specific groups of drugs are metabolized 
and eliminated after uptake to the inner ear. The perilymph 
probably harbors enzymes similar to those in plasma, that can alter 
the structure of drugs. Barriers such as tight junctions that limit drug 
uptake to the inner ear will most likely also limit elimination of 
drugs once they have entered the inner ear compartments, leading 
to slow elimination (Hellberg et al., 2010). The major capillary beds 
within the inner ear are associated with the spiral ganglion, the 
stria vascularis and the spiral limbus. Communications between 
the ST and the spiral ganglion (Shepherd and Colreavy, 2004) 
and between the SV and the modiolar space (Rask-Andersen et 
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al., 2006) have been demonstrated and elimination of drugs from 
the perilymphatic compartment probably occurs through the 
vascularized tissues that lie closest to the perilymph. The rate of 
elimination from the perilymphatic compartment is an important 
factor for drug concentration in the cochlea, which in turn affects 
the distribution of the drug towards the apex following, e.g., drug 
application to the RWM. A steady state will be achieved at a 
specific region in the perilymphatic space when the amount of a 
drug eliminated is equal to the diffusion rate along the scala at the 
same point. The drug concentration at more apical regions will 
therefore not exceed the concentration at the base of the cochlea.
Cisplatin-induced ototoxicity
In this thesis cisplatin has been used as a model for exogenous 
inner ear injury. Moreover, cisplatin-induced ototoxicity is a major 
clinical problem and improved knowledge about prevention of 
cisplatin ototoxicity would be of great importance. 
Cisplatin (Figure 3) is a chemotherapeutic agent that has been 
widely used for more than three decades against various solid 
malignant tumors. Its dose-limiting side effects are nephrotoxicity 
and ototoxicity (Rabik and Dolan, 2007). While nephrotoxicity 
can be prevented by increased hydration and forced diuresis, 
there is still no way to prevent cisplatin’s ototoxicity or repair 
the damage it causes. In pediatric cancer patients, loss of hearing 
is particularly disabling as it may hamper the child’s speech, 
Figure 3. The molecular formula of the chemotherapeutic agent cisplatin.
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cognitive, and social development. Cisplatin-induced hearing loss 
may lead to discontinuation of cisplatin therapy (de Jongh et al., 
2003; Ekborn et al., 2004). The cisplatin analog carboplatin is less 
ototoxic but although a switch to carboplatin treatment reduces 
the risk of hearing loss, it can also reduce the chance of cure or the 
time to progression of the cancer (Go and Adjei, 1999).
Hearing loss has been a known side effect ever since cisplatin 
was introduced clinically in the beginning of the 1970s (Higby 
et al., 1974; Rossof et al., 1972). The first signs of ototoxicity 
include hearing loss in the high frequency range, which rarely 
affects hearing perception (Blakley et al., 1994; Coupland et al., 
1991; Higby et al., 1974; Laurell and Borg, 1988; Schaefer et al., 
1985), along with transient or permanent tinnitus (de Jongh et al., 
2003; Ekborn et al., 2004; Higby et al., 1974; Laurell et al., 1996). 
The hearing loss normally develops over days (Grau et al., 1996). 
Patients receiving high dose treatment may develop severe hearing 
loss at lower frequencies, including the speech frequency range 
(Blakley et al., 1994; Coupland et al., 1991; Ekborn et al., 2004; 
Schaefer et al., 1985). Risk factors for cisplatin-induced hearing loss 
include treatment with a single high dose (Laurell and Jungnelius, 
1990) or a high cumulative dose (Coupland et al., 1991; Laurell 
and Jungnelius, 1990), concomitant radiation towards the base of 
the skull (Kolinsky et al., 2010) and young age in pediatric patients 
(Coupland et al., 1991). There is great inter-individual variability 
in ototoxicity; the reason for this is not known but it might be 
explained by differences in metabolic status, pharmacokinetics 
and genetic factors. In a study of survivors of testicular cancer, 
cisplatin-induced long-term hearing impairment was found to 
be associated with specific genotypes of glutathione S-transferase 
(Oldenburg et al., 2007), an enzyme known to be involved in the 
glutathione antioxidant system.
The primary cytotoxic effects of cisplatin are believed to 
be mediated by the monohydrated cisplatin complex (MHC), 
which reacts with nuclear DNA, forming platinum-DNA adducts 
(Siddik, 2003). The cytotoxicity includes the generation of reactive 
oxygen species (ROS) (Kim et al., 2010). The main targets of the 
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ototoxic effects seem to be the OHC in the Organ of Corti, the 
spiral ganglion cells, and the cells of the stria vascularis in the 
basal part of the cochlea (Rybak, 2007). One explanation for the 
differences in toxicity along the length of the cochlea could be 
that the OHCs in the basal part contain significantly lower levels 
of the antioxidant glutathione than those in the apical part (Sha 
et al., 2001). Another explanation could that the concentration 
of cisplatin is higher at the base of the cochlea than at the apex 
(Hellberg et al., 2010). 
Since one of the mechanisms behind cisplatin-induced 
ototoxicity is believed to be the generation of oxidative 
stress, antioxidants have long been in focus in the search for 
otoprotection (Choe et al., 2004; Nader et al., 2010; Wang 
et al., 2003; Wimmer et al., 2004). Several sulfur-containing 
compounds are antioxidants with high affinity to platinum 
species (Videhult et al., 2006). They may prevent cisplatin- and 
MHC-induced toxicity in a dual manner, both by decreasing 
the effect of ROS and by chelating cisplatin and MHC, forming 
inactive complexes. Among the sulfur-containing antioxidants 
that have shown otoprotective potential in experimental studies 
are N-acetyl-cysteine (Dickey et al., 2005), sodium thiosulfate 
(Dickey et al., 2005), and D-methionine (Campbell et al., 1996). 
However, when administered systemically, such compounds 
may reduce the efficacy of cisplatin-based chemotherapy due 
to drug interactions (Ekborn et al., 2002). Moreover, the uptake 
of antioxidants from the systemic circulation to the cochlea 
is limited due to the blood-labyrinth barrier. Intracochlear 
administration of otoprotective compounds is not a clinical 
option since the human cochlea is located in the base of the 
skull and such treatment would involve invasive surgery that 
may cause irreversible injury to aural sensory structures. Because 
of these limitations there is growing interest in techniques that 
deliver otoprotective substances to the inner ear by way of 
local administration to the middle ear. The fact that it might 
be possible to achieve higher concentrations of a drug by local 
delivery compared to systemic delivery also speak in favor of the 
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local administration systems. For clinical application, effective, 
safe and direct methods for delivery of therapeutic molecules to 
the inner ear need to be developed.
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AIMS
The overall aim of the research project presented in this thesis 
was to develop a method for local administration of drugs to the 
middle ear by using a suitable vehicle that can be loaded with 
different kinds of drugs or a combination of drugs for protection 
of the inner ear or treatment of inner ear disease. The specific aims 
of each individual paper were: 
I. To better describe the morphological and immunological 
properties of the round window membrane.
II. To determine the safety of intratympanic administration 
of vehicle to the middle ear by studying the effect of three 
different gels on the middle and inner ear as well as the 
elimination of the gels from the middle ear.
III. To investigate the distribution and elimination of a gadolinium-
containing gel after injection to the middle ear in vivo using 
magnetic resonance tomography.
IV. To study the uptake of a presumed otoprotector to the inner 
ear after systemic administration in vivo.
V. To study the uptake of the same presumed otoprotector to the 
inner ear after local administration of a vehicle to the middle 
ear and to study the potential effect of the otoprotector against 
experimental inner ear damage in vivo.
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MATERIALS AND METHODS
Laboratory animals (Papers I-V)
All experimental animal studies were performed with permission 
of the local ethical committees for experiments on laboratory 
animals, Direction Départementale des Services Vétérinaires du 
Rhône (France) for the studies performed on cynomolgus monkeys 
and Stockholms Norra Djurförsöksetiska nämnd (Sweden) for the 
studies performed on guinea pigs.
Cynomolgus monkeys (Paper I)
The monkey is closely related to man, having close genetic and 
anatomical similarities. The ears used in Paper I originated from 
cynomolgus monkeys that had been used in a pilot study of a 
commercial drug preceding a phase I study on patients. The non-
injected and the saline-injected control ears, a total of 8 ears from 
6 monkeys, were a kind gift from the pharmaceutical company. 
Ethical permission number: C69-489 and B69-489
Guinea pigs (Papers II-V)
The guinea pig is commonly used in hearing research. It is easily 
bred in captivity. Because the guinea pig cochlea protrudes into 
the middle ear and is not encapsulated in the temporal bone as in 
humans and many other species, the inner ear of the guinea pig 
is accessible for physiological, pharmacological and histological 
studies. The behavioral hearing thresholds are similar to those of 
humans (Prosen et al., 1978). In paper II-V 88 albino guinea pigs 
of both sexes from a local breeder were used.
Ethical permission number: N334/05, N50/07 and N334/08
Auditory brain stem responses (Papers I, II and V)
To analyze electrophysiological hearing thresholds the animals 
auditory brainstem response (ABR) was tested. This is a widely 
used method in which an electric response from nerve cells in 
the auditory pathway is elicited by brief auditory stimuli and 
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recorded via electrodes mounted subcutaneously on the scalp. 
A characteristic curve is obtained with vertex positive waves, 
numbered I-V, corresponding to the different stations in the 
auditory pathway from the cochlea to the brainstem. The 
electrophysiological hearing thresholds of the animals were 
determined by varying the intensity of the stimulus in 5 dB steps 
around the electrophysiological hearing threshold and observing 
the resulting curves. The electrophysiological hearing threshold 
was defined as the lowest level at which a reproducible response 
could be recorded. In Paper I ABR patterns were recorded 
using equipment from Interacoustics AS, model EP 25 (Assens, 
Denmark) and in Paper II and V measurements were performed 
with a TDT system II (Tucker Davies Technologies, Gainesville, 
FL, USA). The sound stimuli were delivered inside the ear canal 
through a speculum from a high frequency transducer with the 
animal placed in a soundproof test box. In Paper II one group of 
animals was used to evaluate whether the vehicles had deleterious 
effects on hearing as assessed using acoustically evoked ABR 
assessments. Thresholds were determined before injection of gel 
to the middle ear cavity and then ABR assessments were repeated 
weekly for three weeks after the administration. In Paper I and 
in the otoprotection study of Paper V the electrophysiological 
hearing thresholds of the animals were verified as being normal 
before start of the experiment and treatment.
Morphological examination using light (Papers I 
and II) and electron microscopy (Paper (I)
The anesthetized monkeys in Paper I were fixed through intra-
cardiac perfusion and the ears were dissected out. After decalci-
fication, the temporal bones were stained in osmium tetroxide. 
The round window niche was dissected out, positioned, and 
sectioned serially at a transverse cutting angle and subsequently 
embedded in EPON epoxy resin and sectioned for light micros-
copy and transmission electron microscopy. Serial semi-thin 
sections for light microscopy were made and every 10th section 
stained with toluidine blue. The specimens were observed and 
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photographed in a Zeiss Axiophoto microscope (Jena, Germany). 
Areas of interest were sectioned for transmission electron micros-
copy through a re-embedding technique. The semi-thin sections 
were glued on a plastic holder, and ultra-thin sections were cut 
and stained with lead citrate and uranyl acetate and then exam-
ined and photographed in a transmission electron microscope, 
JEOL 100 SX TEM (Tokyo, Japan). 
The auditory bullae of the guinea pigs that were to be used 
for light microscopic examination in Paper II were quickly 
disassembled from the temporal bone and fixed after decapitation 
of the deeply anesthetized animals. The bullae were decalcified, 
embedded in JB4 resin (Polyscience), and sectioned at 3-µm 
thickness with a rotary microtome (Microm HM 355 S). The left 
ears were sectioned perpendicularly to the RMW and across the 
cochlea. The right ears were sectioned perpendicularly both to the 
RWM and the TM across the middle ear and the cochlea. Every 
10th section was mounted on a glass slide, stained with toluidine 
blue, and examined under a light microscope (Zeiss) equipped 
with a digital camera (Altra 20 soft imaging system, Olympus). 
The thickness of the RWM and the TM was measured using image 
analysis software (Cell, Olympus).
Gels (Papers II, III and V)
For drug administration to the middle ear, candidate vehicles with 
a high viscosity, for simplicity called gels in this summary, were 
investigated in Paper II. These gels were composed of the polymers 
sodium carboxymethyl cellulose (0.5% w/w) (NaCMC), sodium 
hyaluronate (0.5% w/w) (Na HYA), and poloxamer 407 (25% w/w) 
(POL), respectively. For semi-quantification of the elimination of 
the vehicles from the middle ear cavity the vehicles were mixed 
(5:95, v/v) with coal suspension. 
A hyaluronan (0.5% w/w) gel containing gadolinium-
diethylenetriamine pentaacetic acid-bis methylamine (Gd-DTPA-
BMA) at a concentrati on of 2% w/w was used in the studies on 
which Paper III is based. For the in vitro release studies in this 
paper a gel composed of Gd-DTPA-BMA (2% w/w) in hyaluronan 
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(0.5% w/w) and carbopol (1% w/w) was prepared as well as the 
same gel without hyaluronan, as a reference. 
A thiosulfate-containing (0.10 M) hyaluronan (0.5% w/w) gel 
was used for the in vivo studies of Paper V. A control gel without 
sodium thiosulfate was also prepared. For the in vitro studies in this 
paper the gels also contained carbopol (1% w/w) and a reference 
gel containing thiosulfate (0.10 M) in carbopol (1% w/w) was also 
prepared. 
A phosphate buffer (about pH 7.2) containing NaCl (9 mg/
ml) was used for preparation of all the gels described above. All 
vehicles were autoclaved before being administered in vivo to the 
animals. The osmolality of the thiosulfate-containing (0.10 M) 
hyaluronan (0.5% w/w) gel was about 340 mOsm/kg, which is 
slightly higher than that of blood and inner ear fluids (Sterkers et 
al., 1984).
Rheological measurements (Paper II)
Rheology is the study of materials with both solid and fluid 
characteristics and is commonly used for characterizing polymer 
solutions or gels. According to a rheological definition a gel is a 
material in which the elastic properties dominate over the viscous 
properties (Almdal et al., 1993; Ross-Murphy and McEvoy, 
1986). The rheological properties of the three gels of Paper II 
(NaCMC, NaHYA and POL) were investigated using a Bohlin 
VOR Rheometer (Bohlin Reologi, Lund, Sweden), a controlled 
rate instrument of the couvette type (Bohlin, 1988). Prior to the 
measurements the gels were transferred to a concentric cylinder 
(C8) and centrifuged to remove entrapped air. Silicon oil was 
added to the surface to prevent evaporation. Viscosimetric 
measurements were then carried out on NaCMC and NaHYA at 
37ºC, and oscillating measurements were performed on POL at 
20, 25, 30, 35, and 40ºC.
Drug release studies (Papers III and V)
The drug release studies were performed using a modified USP 
paddle method. The set-up used was a Pharma Test PTWIIUSP 
bath (Pharma Test Apparatebau, Germany) incorporating six 
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beakers in which custom-made sample containers could be 
immersed. The sample container was filled with the different gels 
and then covered with a coarse-mesh plastic net, with the purpose 
of hindering diffusion of the polymers, followed by a stainless 
steel net to prevent gels from expanding or changing shape in the 
container. Finally the container was screwed together with its top 
section. 
The gel containers were immersed in 300 ml drug release 
medium, usually comprised of NaCl (9 mg/ml). The volume 
was chosen so that the absorbance for each drug remained at 
detectable levels throughout the entire experiment and care was 
taken to make sure of all the release studies were performed under 
sink conditions.
With the help of a peristaltic pump and ismaprene tubing 
(Ismatec SA, Zürich, Switzerland), the receiving medium was 
continuously pumped through a UV-vis spectrophotometer 
(Schimadzu UV-1601, Schimadzu, Kyoto, Japan). The absorbance 
was measured automatically at regular intervals. Three 
measurements were performed on each gel and the absorbance 
data was used to approximate the Fickian diffusion coefficient for 
each experiment. 
Local administration of gels to the middle ear cavity 
(Papers II, III and V)
Local administration of the different gel formulations (Papers 
II, III and V) was performed by injection to the auditory bulla 
through the skin of the auricle (volume: 0.15 mL; needle: BD 
Microlance™ 30G, external diameter 0.3 mm). Prior to the 
injection, a myringotomy of the tympanic membrane was made 
to evacuate air. An operating microscope was used to determine 
the point of injection and to observe the flow of the vehicle into 
the middle ear cavity.
In Paper III, where magnetic resonance imaging (MRI) was 
used to study the distribution and elimination of a hyaluronan 
gel, two additional routes of injection were employed. By using a 
catheter for injection to the middle ear it was possible to compare 
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the intensity of the middle and inner ear before and after injection 
without having to move the animals out of the MRI scanner and 
recalibrate. In both these groups of animals the gel was injected 
through a catheter entering the middle ear cavity through a hole 
drilled in the auditory bulla. In one group a myringotomy was 
made in the tympanic membrane prior to injection and in the 
other group the tympanic membrane was left intact.
Visual semi-quantification of coal-marked vehicle 
by opening the bulla (Paper II)
The three different candidate gels for middle ear administration 
investigated in Paper II, NaCMC, NaHYA, and POL, were marked 
with coal. After middle ear administration of the coal-marked gels 
the animals were allowed to wake up. They were reanesthetized 
one, two, or three weeks after the administration and the auditory 
bullae were opened, using a dorsolateral approach. All ears were 
carefully examined in the dissecting microscope for remnants of 
the coal-marked vehicles and signs of inflammatory response in 
the middle ear. Quantification was performed with a four-graded 
scale, shown in Table 1. 
Stage Criteria
A No visible signs of NaCMC, NaHYA, POL, or coal;
no visible signs of inflammation.
B Visible coal remnants in the middle ear mucosa;
no visible signs of NaCMC, NaHYA, POL, or liquid in the 
middle ear cavity, around the ossicules, or at the round 
window;
no edema in the middle ear mucosa.
C Visible coal remnants around the ossicules and/or at the 
round window;
edema in or reddened middle ear mucosa or liquid in the 
middle ear cavity.
D Middle ear filled with NaCMC, NaHYA, or POL marked 
with coal.
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Magnetic resonance imaging (Paper III)
In the MRI technique a strong magnetic field is used to align the 
magnetization spin of mainly hydrogen atoms in the tissues. If 
radio frequency fields are then applied in a certain way the spin 
of the hydrogen nuclei might be altered or “flipped”. When the 
“flipped” nuclei return to the aligned state a weak radiofrequency 
signal is emitted at the resonance frequency. The resonance 
frequency is proportional to the magnetic field strength where the 
atoms are situated. The strength of the signal is proportional to 
the number of atoms excited and returning to aligned state, i.e. 
the amount of water in the tissue. An image can be constructed 
if the magnetic field is systematically varied regarding strength 
and alignment inside the body during the data acquisition. The 
standard basic scans are the T1-weighted scans in which fat is 
bright and water dark. These scans are produced using a gradient 
echo sequence with short echo time and short repetition time. 
MRI in Paper III was performed using a 4.7 T MRI system (Bruker 
Medizintechnik GmbH, Karlsruhe-Ettlingen, Germany) with a 
bore diameter of 400 mm, a shielded 200 mT/m gradient system 
(Bruker BGA-12) and a circular coil with a diameter of 72 mm. 
Three-dimensional (3D) MR images were recorded using the 
spin echo rapid acquisition with relaxation resolution technique 
(Hennig et al., 1986). A recovery time that yielded a high resolution 
T1-contrast was selected. Paravision 4.0 (Bruker) software was used 
for post-processing of the images.
Systemic administration of cisplatin  
and thiosulfate (Papers IV and V)
Thiosulfate (0.20; 3.3 ml/kg b.w.; mean infusion time: 22 s; Paper 
IV) and cisplatin (1 mg/ml; 8 mg/kg b.w.; mean infusion time: 
about 3 minutes; Paper V) were administered systemically under 
direct visual control through a catheter inserted into the internal 
jugular vein to ensure a reliable, reproducible, and relevant drug 
administration in the animal studies.
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Sampling in vivo (Papers IV and V)
Perilymph samples were aspirated from ST to evaluate the 
concentration of thiosulfate in Paper IV and V. Sampling was done 
through a hole drilled in the basal turn of the cochlea, which was 
accessed by opening the bulla of the animal. A micromanipulator 
was used to lower a 1-µl syringe into the drilled hole as quickly 
as possible to avoid leakage of perilymph. One microliter of ST 
perilymph was then gently aspirated.
Blood samples of about 0.35 ml were drawn through a 
catheter inserted into the internal jugular vein (Paper IV and 
V). In Paper IV, blood sampling was performed from the vein 
contralateral to the vein that was used for drug administration. 
After each blood sampling, an equal volume of NaCl (9 mg/
ml) was given to the animals in order to rinse the catheter and 
to replace lost fluids.
Samples of cerebrospinal fluid (CSF) were taken immediately 
after each perilymph sampling (Papers IV and V). The idea was to 
estimate how a potential CSF contamination of the perilymph 
samples might have influenced the quantitative analysis of 
thiosulfate. CSF was aspirated from the cisterna magna using 
a suboccipital approach. Puncture of the cisterna magna was 
performed after exposure of the dura mater (Paper IV) or 
percutaneously (Paper V).
Samples of the thiosulfate-containing hyaluronan gel 
formulation were aspirated with a syringe after opening of the 
auditory bulla, two and three hours after injection to the middle 
ear. The samples were then analyzed to determine the remaining 
concentration of thiosulfate in the gel. 
Thiosulfate analysis (Papers IV and V)
Thiosulfate in samples from perilymph, blood, CSF and 
hyaluronan gel (Paper IV and V) was derivatized with the reagent 
monobromobimane prior to analysis using liquid chromatographic 
separation on a self-packed strong anionic exchange column with a 
mobile phase of succinate buffer (36 mM; pH 5.0) and acetonitrile 
(2:1, v/v) and fluorescence detection (lex=excitation wave length: 
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396 nm; emission wave length: 476 nm). The method was adapted 
from a study found in the literature (Togawa et al., 1992).
Surface preparations (Paper V)
Surface preparations for hair cell counting were used in the 
otoprotection study of Paper V to evaluate the extent of cisplatin-
induced ototoxicity. Cochleae were fixed by perfusion and bone 
was dissected away. The cell cytoskeletons were then stained with 
a fluorescence dye connected to the fungal poison phalloidin. 
Under a fluorescence microscope (Zeiss-Axioplan) the hair cell 
loss was assessed semi quantitatively and compared to a historical 
normative material. The absence of stereociliary bundles and scar 
formation were criteria for hair cell loss.
Statistics
The Wilcoxon signed-rank test was used to compare repeated 
measurements on the electrophysiological thresholds (Paper 
II) and to calculate approximate 95% confidence intervals for 
median difference in hair cell loss between the control ear and 
the thiosulfate-treated ear (Paper V). Two-tailed Mann–Whitney 
test was used to compare two independent groups (Paper V). To 
compare more than two groups, Kruskal–Wallis (Paper II and V) 
and Friedman test (Paper V) were employed for independent and 
dependent groups, respectively. Dunn’s multiple comparison test 
was employed to see which groups differed from which other 
groups (Paper II and V). Fisher’s exact test was used to test if the 
uptake of the contrast agent in the inner ear was significantly 
related to injection technique in Paper III. 
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RESULTS
The round window membrane (Paper I and II)
In all eight ears from the six monkeys examined in Paper I, the rim of 
the RWM displayed a rich network of capillaries, lymph channels, 
and sinusoidal veins frequently containing white blood cells. 
Free cells including macrophages and plasma cells were observed 
in the loose tissue. In two ears from two different animals, the 
RWM displayed conspicuous glandular formations, which were 
harbored in the loose connective tissue of the mucosal layer near 
the bony insertion of the RWM. The gland-like structures found 
in these primates seemed to actively secrete mucous material into 
the middle ear lumen and external surface of the RWM (Figure 4). 
The thickness of the RWM in normal, unexposed control 
guinea pig ears in Paper II was close to 10 µm, which correlated 
well with a previous study (Saber et al., 2009).
Studies of vehicle (Paper II, III and V)
Rheological measurements in vitro (Paper II)
The rheological investigations showed that both NaCMC and 
NaHYA should be considered as highly viscous solutions rather 
than gels. At the shear rates studied, NaCMC thinned in response 
to shear forces, whereas NaHYA did not. POL formed a semisolid 
gel and its rheology changed drastically at a temperature of about 
15ºC. POL thus also fulfilled the rheological definition of a gel, 
which entails having a frequency-independent elastic (G’) modulus 
and a much higher elastic than viscous (G’’) modulus over a large 
frequency range.
Drug release studies (Paper III and V)
In vitro studies 
Gd-DTPA-BMA and thiosulfate diffused quickly out of the 
matrixes in the in vitro studies of Paper III and V; the diffusion rates 
were independent of the presence of HYA with a mean diffusion 
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coefficient (±SD) 2.35 10-7 ±2.2 10-8 cm2/s for Gd-DTPA-BMA 
and 9.57 10-6 ± 0.21 10-6 for thiosulfate. After a few hours most of 
the Gd-DTPA-BMA and thiosulfate had left the formulation. This 
tells us that the HYA formulation does not impede the release 
of either Gd-DTPA-BMA or thiosulfate and indicates that this 
polymer does not reduce the uptake speed of a drug when the gel 
is applied in the middle ear cavity.
In vivo studies 
The HYA gel containing Gd-DTPA-BMA showed constant signal 
intensity during the first three hours of measurements by MRI in 
Paper III.
After one hour (1-h gel group) and three hours (3-h gel group) 
most of the thiosulfate remained in the HYA gel aspirated from 
the middle ear in the studies on which Paper V is based. The 
Figure 4. Light microscope view of the round widow membrane in one of the 
two cynomolgus monkeys displaying conspicuous glandular formations at the rim 
of the round window membrane. These gland-like structures (GS) were actively 
secreting mucous material (m) into the middle ear (ME) lumen and external 
surface of the round window membrane. Scala tympani (ST) (bar = 400 mm)
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median thiosulfate concentrations were 99 mM (range 31–120 
mM, n = 8) and 90 mM (range 75–110 mM, n = 6) in the 1-h and 
3-h gel groups, respectively. The difference between the groups 
was not significant.
Distribution and elimination of the three vehicles 
after injection to the middle ear (Paper II and III)
The visual semi-quantification of gel elimination in vivo (paper 
II) showed that NaHYA was eliminated from the middle ear 
faster than NaCMC and POL. In NaHYA-injected ears, only coal 
remnants were found in the middle ear three weeks after injection. 
In the other two groups there were also signs of inflammation and 
gel remnants in the middle ear at three weeks.
In Paper III, the best filling of the middle ear was achieved by 
the injection technique where the Gd-DTPA-BMA-containing 
HYA gel was delivered to the middle ear through a percutanous 
injection through the auditory bulla after a small incision had 
been made in the tympanic membrane. When this was done, 
the gel covered the cochlea, including the region of the round 
Figure 5. Hyaluronan gel (0.5% w/w) containing a paramagnetic contrast agent 
injected to both the right and left middle ear by a percutanous injection through 
the auditory bulla of guinea pig. The middle ears were almost completely filled 
with HYA gel, which was covering the cochleae (arrows) and the region of the 
round window membrane at the base of the cochlea.
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window niche (Figure 5). The gel continued to cover the cochlea 
at 24 h in 9 out of 12 examined ears and at 48 h in 4 out of 9 
examined ears. The two ears imaged at 72 h and one at 96 h 
showed gel remnants only at the base of the cochlea and not 
in the region of the round window niche. Ears injected without 
an incision in the tympanic membrane displayed an immediate 
uptake of Gd-DTPA-BMA in the inner ear, which is taken as a 
sign of rupture of the round window membrane. 
Effects of the three vehicles on middle  
and inner ear (Paper II)
In the studies on which Paper II is based, ABR assessment 
revealed normal electrophysiological hearing thresholds in ears 
injected with NaHYA at one, two or three weeks after injection 
to the middle ear. Conversely, ears injected with NaCMC and 
POL showed threshold shifts throughout the observation time. 
This indicates that the negative effect of NaHYA on sound 
transmission is eliminated faster than the effects of the two other 
gels. The electrophysiological hearing thresholds shifts of the 
Figure 6. Guinea pigs were subjected to an intratympanic injection (0.15 mL) 
of sodium carboxymethyl cellulose (0.5% w/w) (A), hyaluronan (0.5% w/w) 
(B), or poloxamer 407 (25% w/w) (C). Acoustically evoked auditory brainstem 
response (ABR) assessment was performed before as well as one, two, and 
three weeks after the injection. The graphs show the electrophysiological 
hearing threshold shifts, i.e. the difference between the hearing thresholds 
obtained before and after (one week, open circles; two weeks, closed circles; 
three weeks; open triangles) the injection. Data are expressed as mean± SEM. 
The measured frequencies, 3, 6, 12, 20, and 30 kHz, are center frequencies of 
the presented auditory stimuli. 
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three groups of guinea pigs after injection of the different gels to 
the middle ear are shown in Figure 6.
Due to technical problems in the morphological study 
of Paper II, few observations could be done. Moreover, the 
number of successful observations differed between the three 
groups, making it difficult to draw any significant conclusions. 
However, no remnants of the vehicle and no signs of mucosal 
inflammation were found in the ears injected with NaHYA, 
whereas vehicle remnants and a swollen middle ear mucosa was 
found in animals injected with NaCMC. The mucosa was also 
swollen in POL-injected ears but no remnants of the vehicle 
could be seen. There were no signs of damage to the hair cells 
or SV in the basal turn the cochlea, close to the RWM in any of 
the ears that were examined.
Drug distribution to the inner ear  
(Paper IV and V)
Systemic administration of thiosulfate (Paper IV)
Thiosulfate was rapidly and extensively distributed to the 
perilymph of the ST after i.v. administration. The area under the 
median concentration–time curve of ST perilymph and blood 
ultra-filtrate was 3100 µM x min and 6300 µM x min, respectively. 
The elimination of thiosulfate from perilymph of the ST was 
slower than that from blood, resulting in higher concentrations 
of thiosulfate in perilymph at the end of the observation period, 
three hours after injection (Figure 7).
The thiosulfate concentrations in CSF were well below those 
in ST perilymph and blood ultrafiltrate at the same target times.
Local administration of thiosulfate (Paper V) 
The median concentrations of thiosulfate in ST perilymph after 
local administration of a thiosulfate-containing HYA gel to the 
middle ear of the guinea pig in Paper V were 137 µM (range 14.5–
312 µM, n=7) and 148 (range 57.4–912 µM, n=7) in the 1-h and 
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Figure 7. Concentrations of thio-
sulfate in blood (closed circles) 
and scala tympani perilymph 
(open circles) of guinea pigs after 
an i.v. bolus injection of thiosulfate 
(0.20 M; mean injection volume: 
1.28 ml). Each symbol represents 
one sample. The broken lines con-
nect the median concentration of 
thiosulfate at each sampling time 
point in blood as well as in peri-
lymph.
Figure 8. Concentration of 
thiosulfate in scala tympani peri-
lymph of guinea pigs after an 
i.v. bolus injection of thiosulfate 
(0.20 M; men injection volume: 
1.28; filled triangles) and in-
tratympanic injection (0.10 M 
in hyaluronan (0.5% w/w) gel; 
mean injection volume: 0.17 ml; 
open and closed circles). The 
gel was removed after one hour 
(closed circles) or three hours 
(open circles) prior to perilymph 
sampling. Each circle and tri-
angle represents one sample. 
The thiosulfate concentrations 
in scala tympani perilymph were 
significantly higher (indicated with 
a star) in the gel groups compared to the i.v. group 120 and 180 minutes after the i.v. 
administration. The broken lines connect the median concentrations of thiosulfate 
at each sampling time point in the i.v. group as well as in the gel groups.
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3-h gel groups, respectively. No significant difference was found 
between the two groups.
Figure 8 shows the concentrations of ST perilymph from the 
1-h gel group, the 3-h gel group (Paper V) and the group treated 
with thiosulfate i.v. (Paper IV). The local administration system 
gave a significantly higher concentration of thiosulfate in ST 
perilymph of the basal turn compared to the i.v. administration, 
even though the amount of thiosulfate given locally was only 7% 
of the i.v. dose.
The thiosulfate concentration in blood after intratympanic 
administration remained low during the entire study in both the 1- 
and 3-h gel groups as shown in Figure 9. There was no significant 
difference between the 1-h gel group and the 3-h gel group. The 
thiosulfate concentration was low in CSF samples taken at the end 
Figure 9. Concentrations of thiosulfate in blood of guinea pigs treated with 
a thiosulfate-containing (0.10 M) hyaluronan (0.5% w/w) gel (mean injected 
volume: 0,17 ml) applied in the middle ear for one hour (1-h gel group; A) or 
three hours (3-h gel group; B) Each symbol represents one animal and each 
animal was sampled three times in the 1-h gel group and four times in the 
3-h gel group. The solid horizontal lines show the approximate endogenous 
thiosulfate concentration in the guinea pig and the solid vertical lines indicate 
the mean time of removal of the gel.
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of the experiment. The median concentration of thiosulfate was 
0.80 µM (range 0.67–0.86 µM, n=6) in the 1-h gel group and 0.81 
µM (range 0.70–1.0 µM, n=6) in the 3-h gel group. 
Otoprotective effect of a locally administered 
thiosulfate-containing gel against cisplatin induced 
ototoxicity (Paper V)
A protective effect against cisplatin-induced ototoxicity 
obtained by middle ear application of thiosulfate (0.1 M) in 
HYA gel three hours prior to cisplatin administration (8 mg/
kg b.w., i.v.) was confirmed. Ten out of eleven animals with 
damaged control ears exhibited only minor OHC loss in the 
ear treated with thiosulfate-containing HYA gel. No inner hair 
cell loss was seen in any of the ears. Cytocochleograms from 
cisplatin-treated guinea pigs, representing the median OHC loss 
in control ears and in ears treated with a thiosulfate-containing 
HYA gel prior to cisplatin treatment are shown in Figures 10A 
and 10B, respectively. 
Figure 10. Cytochocleograms for cisplatin-treated guinea pigs (8 mg/kg b.w., 
i.v.) showing loss of outer hair cells (OHCs) in control ears (A) and ears treated 
with a thiosulfate containing (0.10 M) hyaluronan (0.5% w/w) gel (B). The gel 
was injected to the middle ear cavity three hours prior to administration of 
cisplatin. Inner hair cells (IHCs) are represented by open triangles and OHCs 
in the first row by filled circles, in the second row by open circles and in the 
third row by closed triangles. Data are expressed as median values.
50
The difference in OHC loss between the control and the thiosulfate-
treated ears of each animal was calculated and the median values 
are presented in Figure 11. The difference observed in the basal 
turn of the cochlea was considered significant as the approximate 
95% confidence interval did not overlap, y=0. 
Figure 11. Cytocochleograms for cisplatin-treated guinea pigs (8 mg/kg b.w. 
i.v.) showing difference in loss of outer hair cells (OHCs) between control 
ears and ears treated with a thiosulfate-containing (0.10 M) hyaluronan (0.5% 
w/w) gel. The gel was injected to the middle ear cavity three hours prior to 
administration of cisplatin. The closed circles, open circles, and closed triangles 
represent the OHs in the first, second, and third rows, respectively. Data are 
expressed as medians with approximate 95% confidence intervals.
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DISCUSSION
Therapeutic management of inner ear disease is an expanding 
scientific field. Advances in molecular biology and especially in 
the basic understanding of mechanisms associated with inner 
ear disease will lead to new approaches for treatment of the 
large group of patients who suffer from inner ear disorders. The 
cochlea, embedded in the petrous part of the temporal bone, is a 
particularly challenging target for pharmacological treatment and 
new technologies will be required to provide safe and efficacious 
delivery of medication to the inner ear. It was hypothesized at 
the start of this doctoral project that local administration of an 
antioxidant to the middle ear provides protection against an 
ototoxic injury. A fundamental idea was that intratympanic drug 
delivery circumvents some of the problems associated with systemic 
delivery, such as drug interaction and systemic side effects.
The local delivery systems used in this thesis were high viscosity 
formulations injected to the middle ear, serving as vehicles for 
drugs aimed for inner ear treatment. The main and chronologically 
last finding was that thiosulfate-containing (0.1 M) HYA gel (0.5% 
w/w) injected to the middle ear three hours prior to i.v. injection 
of cisplatin (8 mg/kg) protected against OHC loss in the guinea 
pig. Prior to this final study presented in paper V various aspects of 
local drug delivery to the inner ear were first elucidated.
Round window membrane  
– a route for drug delivery
First, the morphological and immunological properties of the 
RWM were investigated. This membrane is believed to be the 
primary route for drug transport from the middle to the inner 
ear. The experiments aimed to provide deeper understanding of 
mechanisms that might influence this transport. The study on 
which Paper I is based was performed on the cynomolgus monkey, 
a primate closely related to the human being. A rich network 
of capillaries, lymph channels, and sinusoidal veins frequently 
containing white blood cells were displayed at the rim of the 
52
RWM. In the loose connective tissue free cells, including plasma 
cells and macrophages, were identified. Conspicuous glandular 
formations at the bony insertion of the RWM were observed in 
one third of the animals. Such formations have not previously 
been described in the literature. The findings suggest that a local 
defense system is housed within the rim of the RWM. This could 
explain why labyrinthitis is rare, even though the middle ear is an 
area prone to infections (Hyden et al., 2006; Kitsko and Dohar, 
2007). A local immunodefense system in the inner ear has earlier 
been suggested, with the endolymphatic sac playing a central role 
(Couloigner et al., 2004; Garcia Berrocal and Ramirez-Camacho, 
2000; Harris and Ryan, 1995; Harris et al., 1997). Still the RWM 
most probably represents one of the major pathways for possible 
transport of toxins and infectious material from the middle ear 
into the ST and inner ear. Moreover high-frequency SNHL 
both in animals and patients with otitis media strongly suggest 
preferential involvement of the cochlear basal turn (Cureoglu et 
al., 2004; Joglekar et al., 2010; Paparella et al., 1980; Schachern 
et al., 1992). The local immunodefense system appears to involve 
mucin secretion from goblet cells and specific action via white 
blood cells, including monocytes/macrophages acting as a first 
line of defense. The second line of defense most probably entails 
integrated, specific functions involving immunocompetent cells 
(e.g., plasma cells) with antigen trapping and processing, leading 
ultimately to degradation and detoxification of the invader or 
invading material. These mechanisms all involve the cascades 
of specific immunoreactions with complex interactions between 
cell components, cell trafficking, and local humoral interaction. 
During a mild inflammatory response induced by injection of 
NaCl (9 mg/ml) to the middle ear, the mucosa was found to be 
slightly swollen at the RWM towards the middle ear. At the same 
time, the number of free cells within the subepithelial space in 
the round window niche increased, as did the number of white 
blood cells in the blood vessels. An increased thickness of the 
RWM was also seen in the saline-injected ears of guinea pigs in 
Paper II, strengthening the impression of a locally developed 
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immunodefensive system at the round window. The inflammatory 
alterations localized to the RWM seen in both the cynomolgus 
monkey and the guinea pig indicate that permeability of the 
RWM may undergo dynamic changes in response to instillation 
of exogenous products to the middle ear cavity. 
An activation of the immunodefense system of the RWM 
could affect the membrane’s transport properties in several ways; 
such changes would also influence drug delivery when a drug is 
applied locally to the middle ear for treatment of the inner ear. 
This might explain some of the inter-individual variability in drug 
uptake into the inner ear after application in the middle ear and 
at the RWM (Hahn et al., 2006; Mikulec et al., 2008). Thickening 
and microscopic signs of inflammation in the RWM have been 
observed when drugs and vehicles have been applied to the RWM 
or intratympanically (Nordang et al., 2003; Saber et al., 2009). Drug 
solution osmolarity, benzyl alcohol content and possible drying 
of the RWM during suctioning of the middle ear, have all been 
shown to influence the permeability of the RWM (Mikulec et al., 
2008). It has been suggested that manipulations of the RWM that 
initially increase permeability, subsequently result in thickening 
and scarring (Goycoolea, 2001) that could reduce permeability for 
later attempts at inner ear drug delivery. Injury to the local defense 
system by manipulation may make the inner ear more susceptible 
to toxins and direct spread of microorganisms that are present in 
a non-sterile middle ear space. All these factors may influence the 
drug transport to the inner ear from the middle ear and need to 
be taken into consideration when developing new technologies for 
drug delivery. 
Vehicles for drug delivery to the inner ear
The second study (Paper II) studied the rheological properties of 
three different high viscosity formulations aimed for intratympanic 
drug administration: NaCMC, NaHYA (called HYA in the 
following papers III and V) and POL. Their safety was also assessed.
Sodium hyaluronate, which was used for preparation of NaHYA, 
is the sodium salt of hyaluronic acid. In the literature, hyaluronan 
54
is used as a general term for this polymer, irrespective of its degree 
of dissociation (Balazs et al., 1986). Hyaluronan occurs naturally 
in humans, particularly in the synovial fluid, the umbilical cord, 
the nasal cartilage, and the vitreous body (Laurent and Fraser, 
1992). It has also been found in the inner ear (Friberg et al., 1989). 
Locally applied exogenous hyaluronan has been used for a long 
time in otological research, both in experimental animals (Angeli 
et al., 2007; Anniko et al., 1987; Bagger-Sjoback, 1991; Bjurstrom 
et al., 1987; Dogru et al., 2009; Krupala et al., 1998; Laurent et al., 
1991; Saber et al., 2009) and humans (Angeli et al., 2007; Arriaga 
and Goldman, 1998; Bagger-Sjoback et al., 1993; Engstrom et 
al., 1987; Gouveris et al., 2005; Selivanova et al., 2005; Stenfors, 
1987). These studies have shown that hyaluronan is well tolerated 
and not ototoxic, even when administered into the middle ear 
under conditions that have allowed direct access to the inner ear 
(Bagger-Sjoback, 1991; Laurent et al., 1991). The light microscopic 
investigation described in Paper II showed that NaHYA induced 
less thickening of the RWM and TM than the other two vehicles, 
NaCMC and POL. The effect of NaHYA on the RWM agrees with 
that of a previous study, in which a similar hyaluronan vehicle 
was used to study neomycin transport from the middle ear to the 
inner ear after intratympanic injection (Saber et al., 2009). In the 
study of Saber et al., the thickness of the RWM returned to normal 
values after four weeks. Exogenous hyaluronan is reported to be 
eliminated from the middle ear cavity primarily via the Eustachian 
tube (Laurent et al., 1986). It may be totally eliminated within a day 
in the rat, according to an experimental study using a vehicle with 
a hyaluronan concentration twice that of the present investigation 
(Laurent et al., 1986). However, results of the semi-quantitative 
study (paper II) using NaHYA marked with coal indicate that a 
hyaluronan-based vehicle may stay in the middle ear considerably 
longer in the guinea pig. An important finding was that NaHYA 
did not induce any significant shifts in the electrophysiological 
hearing threshold one, two, and three weeks after administration 
of NaHYA. Neither were any remnants of NaHYA in the middle 
ear found in the light microscopic investigation six days after its 
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administration to guinea pigs (paper II). In the present project, 
the hyaluronan concentration was not varied, but it is well known 
that the viscosity of a hyaluronan gel is directly proportional to 
its concentration (Lapcik et al., 1998). Even though this was not 
examined it is probable that the elimination rate of a hyaluronan 
vehicle from the middle ear cavity would be reduced when the 
concentration of hyaluronan is increased. 
Sodium carboxymethyl cellulose is a widely used additive 
in different pharmaceutical formulations, mostly as a viscosity 
modifier, but also as an emulsifier (Wade and Weller, 1994). It is 
also used in artificial teardrops. In the present study, NaCMC was 
found to be pseudoplastic, which means that the carboxymethyl 
cellulose molecules were deformed and realigned in the streamlines 
of flow, resulting in a decrease in the viscosity. This behavior 
occurs when a pseudoplastic formulation is forced through the 
needle of a medical syringe, which facilitates injection. In contrast, 
NaHYA did not exhibit a shear thinning behavior. Nonetheless, 
hyaluronan has been shown to be pseudoplastic when a higher 
shear force is applied or when it is less concentrated (Lapcik et 
al., 1998). Sodium carboxymethyl cellulose is considered nontoxic 
and non-irritant, and is employed also as a food additive (Wade 
and Weller, 1994). However, in contrast to hyaluronan, there 
are few published studies on the use of sodium carboxymethyl 
cellulose in otological research. The results of the present study 
show that NaCMC might be less convenient for intratympanic 
administration than NaHYA. In fact, sodium carboxymethyl 
cellulose might even be ototoxic, according to recently published 
data from a guinea pig study (Antonelli et al., 2010). However, that 
study used a commercial formulation (Sinu-Foam) intended for 
nasal application and it is unknown whether the hearing loss was 
caused by sodium carboxymethyl cellulose itself or by some other 
component or property of the formulation. 
Poloxamer 407 is a polyoxyethylene block copolymer used in 
several different pharmaceutical preparations, both for internal 
and topical use. Poloxamers respond to changes in temperature, 
being less viscous when refrigerated or at room temperature than 
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at body temperature. To facilitate the intratympanic injection in 
the present study, samples of POL were taken from the refrigerator 
immediately prior to the injection. Despite this precaution, the 
viscosity of POL was still high, and to avoid excess trauma to the 
TM, POL (as well as NaCMC and NaHYA) was injected through 
the auditory bulla. Similar to sodium carboxymethyl cellulose 
and hyaluronan, poloxamer 407 is considered nontoxic and non-
irritant (Wade and Weller, 1994). Nonetheless, the results of the 
present study imply that POL is less suitable for intratympanic 
administration than NaHYA. In particular, POL induced a 
striking thickening of the TM and had substantial effects on 
the electrophysiological hearing thresholds in the guinea pig. 
However, according to recent publications, poloxamer 407 may 
also be well tolerated when administered into the middle ear (Piu 
et al., 2011; Wang et al., 2009). In one of the cited studies, most 
of the conductive hearing loss had disappeared about four weeks 
after intratympanic administration of poloxamer 407 (Piu et al., 
2011), and several weeks earlier in two other studies (Salt et al., 
2010; Wang et al., 2009). These studies used a lower concentration 
of poloxamer 407 (16% and 17% versus 25% in our study) and 
a smaller volume was injected (50 µl versus 150 µl in our study), 
which might explain the more promising results in the other 
studies as compared to those presented in this thesis.
The overall results of paper II speak in favor of NaHYA. 
Especially, in contrast to NaCMC and POL, NaHYA did not cause 
any obvious prolonged conductive hearing loss as determined 
by ABR. The results of the elimination and morphological 
investigations support the conclusion that NaHYA is the most 
promising candidate for intratympanic administration. NaHYA 
was therefore selected for further investigations. In the following 
discussion NaHYA will be called HYA gel.
In vivo study of HYA gel distribution and elimination 
using magnetic resonance imaging
A major concern with local administration of a drug to the inner 
ear using the middle ear route is the adherence of the vehicle or 
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solution to the RWM. The literature offers no detailed information 
about the residence time of a vehicle in the round window niche 
after intratympanic administration. In order to get a more clear 
view of middle ear filling after intratympanic injection, different 
techniques for visualization of the HYA gel were discussed before 
the study in paper III was designed. Moreover, it was also of 
great interest in this phase of the doctoral project to establish the 
optimal technique for injection of HYA gel to the middle ear of 
the guinea pig. Experimental MRI was found to be a suitable tool 
to explore in vivo how a vehicle behaves over time in the middle 
ear after an intratympanic injection. Therefore, this in vivo study 
compared HYA gel distribution and elimination in the middle 
ear cavity after use of three different techniques for intratympanic 
injection. The paramagnetic contrast agent Gd-DTPA-BMA was 
added to HYA gel which was then injected to the middle ear 
of three groups of guinea pigs and investigated using high field 
experimental MRI. The 4.7 T MRI system, using a T1-weighted 
3-dimensional rapid acquisition with relaxation enhancement 
sequence, provided a good visualization of the middle ear and 
cochlea. This non-invasive method made it possible to get a better 
understanding of how HYA gel filled the middle ear. In all three 
animal groups the gel was well distributed and filled the middle 
ear cavity completely, covering the major portion of the cochlea 
and most important the region of the round window niche. In the 
in vitro preparation approximately 70% of the Gd-DTPA-BMA 
had disappeared from the gel within three hours whereas in vivo 
the intensity of marker in the gel did not decrease during the first 
three hours of observation following intratympanic injection. A 
possible explanation for this observation could be that the middle 
ear in this context can be regarded as a semi-closed compartment, 
in contrast to the open conditions in the basins of the in vitro 
study. In this perspective the middle ear could be seen as a reservoir 
for drug transport to the cochlea after intratympanic injection of 
drug-loaded HYA gel. From a clinical standpoint it is important to 
establish that a drug can diffuse freely in and out of the gel and 
that the gel does not retain it in the middle ear cavity. Under in 
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vivo conditions the surrounding mucosa in the middle ear will 
most probably be rapidly saturated with the drug and therefore the 
gel will continue to have a high concentration, allowing passage 
over the RWM for a longer period of time. In the present study 
one could still observe gel with Gd-DTPA-BMA signaling in 
remnants at the base of the cochlea but not in the region of the 
round window niche up to 72 h after injection. This means that 
the residence time of HYA gel in the round window niche was 
shorter than 72 hours, indicating that the effective release of a drug 
from the HYA gel to the inner ear would not exceed 72 hours. 
If local treatment methodologies are to be developed for use in 
human patients, gel residence times in the human round window 
niche should be evaluated in similar clinical MRI studies. 
Injection techniques
The most reliable minimally invasive method for injection to the 
middle ear of the guinea pig was a procedure involving HYA gel 
injection through the skin of the auricle after an incision in the 
upper quadrant of the tympanic membrane. This method allowed 
air to escape as pressure increased and the middle ear was filled with 
the gel in a predictable way. Thus, a true transtympanic injection 
through the tympanic membrane was not used in the following 
study. As a result of earlier studies on experimental animals and 
on patients it is generally accepted that the RWM is permeable 
to Gd-DTPA-BMA and gadolinium-tetra-azacyclo-dodecane-
tetraacetic acid (Counter et al., 1999; Counter et al., 2000; Duan 
et al., 2004; Zou et al., 2010a; Zou et al., 2010b) (Yoshioka et 
al., 2009) (Nakashima et al., 2007; Nakashima et al., 2009). The 
concentration of Gd-DTPA-BMA in the HYA gel (10 mmol/l) 
used in the current study was selected for visualization of the gel 
in the middle ear and not primarily for observation of Gd-DTPA-
BMA uptake in the inner ear. In studies where Gd uptake in the 
cochlea has been shown, considerably higher concentrations of 
Gd-DTPA-BMA and the other gadolinium compound have been 
used (Duan et al., 2004) (Zou et al., 2010a) (Nakashima et al., 2007; 
Nakashima et al., 2009; Yoshioka et al., 2009). It is therefore most 
59
probable that the lack of cochlear uptake seen in groups 2 and 3 in 
which myringotomy was used before injection was due to the low 
concentration of Gd-DTPA-BMA. In contrast, in group 1, which 
was given Gd-DTPA-BMA-containing HYA gel with an intact 
tympanic membrane, Gd-DTPA-BMA was immediately taken up 
into ST, indicating a perforation of the RWM. These data suggest 
that an injection technique without paracentesis of the TM can be 
hazardous to the RWM and likely also to cochlear function. 
Drug transport to the inner ear
Paper II and III identified the HYA gel as a promising vehicle for 
middle ear administration of drugs aimed for inner ear treatment. 
The next step would be to investigate if a drug could actually be 
delivered to the inner ear in measurable concentrations using 
the HYA gel in the guinea pig model. Our research group has 
long experience of research on cisplatin-induced ototoxicity 
and our collaborators at the Karolinska Pharmacy had recently 
identified the endogenous ion thiosulfate (Figure 12) as an 
interesting candidate compound for protection against cisplatin-
induced ototoxicity (Videhult et al., 2006). The next goal was 
to investigate if locally administrated thiosulfate in HYA-gel 
could reach the cochlea to a greater extent than after systemic 
administration and also to establish whether ototoxicity induced 
by cisplatin could be prevented.
Figure 12. The molecular formula of thiosulfate. A sulfur-containing antioxidant 
with otoprotective properties.
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The results from Paper IV and Paper V show that the highest 
concentration of thiosulfate in the basal turn of the cochlea was 
achieved by using the local administration strategy even though 
the amount of thiosulfate given locally was only 7% of the i.v. 
dose (Fig 7). The concentration of thiosulfate in ST perilymph of 
gel-treated guinea pig also remained high for a longer period of 
time, whereas it decreased rapidly in i.v. treated guinea pigs. This 
indicates that thiosulfate was stored in the middle ear, prolonging 
cochlear drug uptake. 
Assessment of thiosulfate in ST perilymph is a common 
method to establish how much of the administered drug has 
reached the inner ear. However, drug concentrations in perilymph 
are not necessarily a good measure for inner ear pharmacokinetics. 
Drug trafficking inside the inner ear is complex and the usefulness 
of the perilymphatic route might vary for different substances, 
depending upon their chemical structure. For example an 
endolymphatic route for gentamicin to cochlear hair cells has 
been suggested (Wang and Steyger, 2009). Thiosulfate was sampled 
from the ST by aspiration of 1 µl of perilymph from the basal 
turn of the cochlea. Sampling from ST in the guinea pig is more 
straightforward than sampling from SV and SM. Moreover, 
sampling from the basal turn of the cochlea does not involve 
as severe a surgical trauma to the animal as sampling from the 
apex does. This type of sampling can therefore be performed 
with fewer effects on the homeostasis of the animal, i.e. the 
samples can be regarded as taken under reasonably physiological 
conditions. In cisplatin-induced ototoxicity the outer hair cell loss 
is most pronounced in the basal turn; thus the concentrations 
of thiosulfate in this part of the cochlea are the most interesting. 
However, one should always consider the risk of contamination 
with CSF during perilymph sampling in the guinea pig (Salt et 
al., 2003) since the open cochlear aqueduct, which connects the 
inner ear with the CSF-filled space in the central nervous system, 
is located at the base of the cochlea near the round window. 
To avoid spillover of perilymph it is important to sample small 
volumes, not to close to the round window, and the sampling 
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should be performed quickly (Hara et al., 1989). The 1-µl samples 
of perilymph that were aspirated from ST as described in Paper IV 
and V are expected to contain about 20% CSF (Hara et al., 1989). 
However, the low concentrations of thiosulfate detected in pure 
CSF samples confirm that the thiosulfate concentrations in ST 
perilymph were more likely underestimated than overestimated. 
The concentrations of thiosulfate in blood after local 
administration were about the same as those in blood 3 hours 
after i.v. administration (c.f.  Figure 8A and 8B to Figure 6). There 
was a large inter- and intra-individual variability in the data shown 
in Figure 8A and 8B but the concentrations of thiosulfate in blood 
from the gel groups were in most cases similar to the endogenous 
levels (indicated with solid horizontal line in Figures 8A and 8B). 
Even in the most extreme cases, when thiosulfate levels reached 
15 µM, the risk that the antineoplastic effects of cisplatin might 
be reduced seems negligible; much higher levels are required for 
inactivation of cisplatin and MHC (Pierre, 2010). 
The in vitro studies of drug release in Paper V showed that 
practically all thiosulfate had disappeared from the gel within 2 h 
whereas in vivo there was still a high concentration of thiosulfate 
when the gel was aspirated from the middle ear 3 h after 
intratympanic injection. These results are in line with the results 
of Paper III and are thought to be due to the closed compartment 
of the middle ear serving as a reservoir for a prolonged drug 
release. This might be of particular importance for protection 
against cisplatin-induced ototoxicity, as cochlear injury develops 
gradually over several days after treatment (Laurell and Bagger-
Sjoback, 1991). However, it has been shown that ototoxicity 
caused by platinum-containing antineoplastic drugs is dependent 
upon the drugs’ pharmacokinetics in the inner ear, particularly 
on the area under the concentration-time curve (Hellberg et al., 
2009). Therefore, the presence of thiosulfate in the cochlea might 
be most critical when the cisplatin concentration in ST perilymph 
is at its highest, which occurs during the first hours after a single i.v. 
injection in the guinea pig (Laurell et al., 1995a). If this is the case, 
the middle ear administration strategy is also superior to systemic 
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administration since it offers higher thiosulfate concentration in 
ST perilymph during the first phase of ototoxicity.
From the results of Paper III and the pharmacokinetic study 
of Paper V we could conclude that injection of a thiosulfate-
loaded HYA gel to the middle ear is a feasible method to obtain 
high concentrations of thiosulfate in the basal turn of cochlea 
while blood levels were maintained low. There are undesireable 
audiological symptoms, such as fullness of the ear, but these are 
temporary. This local administration strategy also seemed to offer 
a continous distribution of thiosulfate to the inner ear. 
Protection against cisplatin ototoxicity by local 
administration of a thiosulfate-containing HYA gel
In the final study of Paper V, the efficacy of the thiosulfate-loaded 
HYA gel against cisplatin-induced ototoxicity was explored. The 
study design included injection of HYA gel to the middle ear 
three hours before cisplatin treatment. This was based on the 
results from the pharmacokinetic study, which showed that the 
lowest concentrations of thiosulfate in perilymph were higher 
in the 3-h gel group than in the 1-h gel group even though the 
median concentrations of thiosulfate in ST did not significantly 
differ between the groups. Evaluation of OHC loss by the use 
of surface preparations of cochleae harvested four days after 
cisplatin administration showed that thiosulfate (0.10 M) in HYA 
gel (0.5% w/w) protected against cisplatin-induced hair cell loss in 
the guinea pig. Thus, the results of this doctoral project support 
the hypothesis that local administration of an antioxidant to the 
middle ear provides protection against an ototoxic injury.
It remains to be established if this local drug delivery system 
can be used to apply drugs to the inner ear of patients. The 
main drawback of this method is most probably the conductive 
hearing loss that will cause temporary discomfort for the patients. 
However, the results from Paper II and III indicate that most of 
the gel was eliminated within a week, and a transient conductive 
hearing loss might be accepted – at least by patients undergoing 
high-dose cisplatin treatment – in order to avoid ototoxic side 
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effects. If the HYA gel were to be used for treatment of ISSHL 
when the patients are already suffering from a hearing loss, this 
issue would be even less relevant. When a prolonged time at 
the site of absorption is desired, a gel or viscous formulation is 
advantageous due to its mucoadhesive (Edsman and Hagerstrom, 
2005) and rheological (Carlfors et al., 1998; Edsman et al., 1998) 
properties. By varying the concentration of the gel or high viscosity 
formulation administered to the middle ear, it will be possible to 
maintain inner ear drug exposure for a desired period of time. 
Moreover, injection of a drug-loaded HYA gel can be repeated.
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CONCLUSIONS
1. The morphological study of the round window in a primate 
showed existence of a local defense system housed within 
the rim of the round window membrane (RWM). Gland-
like structures harbored in the loose connective tissue of the 
mucosal layer near the bony insertion of the RWM were 
identified and seem to be an important part of this local 
immunodefense of the inner ear 
2. Sodium hyaluronate (HYA gel) was found to be a suitable vehicle 
for middle ear administration aimed for pharmacological 
treatment of the inner ear. In contrast to sodium carboxy 
methyl cellulose and poloxamer 407, HYA gel did not 
cause prolonged elevations of electrophysiological hearing 
threshold. The results of the elimination and morphological 
investigations also support the conclusion that HYA gel is the 
most promising candidate for intratympanic administration.
3. Magnetic resonance imaging showed that HYA gel was 
distributed in a predictable way and filled the middle ear 
cavity well after injection into the tympanic bulla in the guinea 
pig. Myringotomy was needed before the middle ear injection 
in order to avoid traumatic damage to the round window 
membrane. The HYA gel remained in close vicinity to the 
round window membrane for more than 24 h.
4. Thiosulfate was rapidly and extensively distributed to the 
perilymphatic compartment of the cochlea after an i.v. bolus 
injection in the guinea pig. The elimination of thiosulfate from 
perilymph was slower than from blood, resulting in higher 
concentrations in perilymph than in blood at the end of the 
observation time, three hours after injection. 
5. Although HYA gel did not inhibit the release of thiosulfate in 
vitro, a high concentration of thiosulfate remained in the HYA 
gel three hours after middle ear administration, indicating that 
drug release to the inner ear is prolonged in vivo.
6. Compared to i.v. administration, local administration of 
thiosulfate by injection of thiosulfate-containing HYA gel 
to the middle ear cavity resulted in higher concentrations of 
65
thiosulfate in perilymph, while levels in blood remained low, 
indicating a low risk of interference with the antineoplastic 
effects of cisplatin.
7. Compared to i.v. administration, local administration of 
thiosulfate by injection of thiosulfate-containing HYA gel 
to the middle ear cavity offered a continuous distribution of 
thiosulfate to the perilymphatic compartment of the cochlea. 
Since cisplatin-induced ototoxicity develops progressively 
over several days, this continuous distribution of thiosulfate 
might help protect the inner ear from damage. This reservoir 
function of the drug delivery system might also be useful for 
treatment of other inner ear disorders where a prolonged drug 
release would be advantageous. 
8. Cisplatin-induced outer hair cell loss was prevented by 
administration of thiosulfate-containing HYA gel to the middle 
ear in a guinea pig model. This supports the idea that the local 
drug delivery system using an intratympanic injection of HYA 
gel as a vehicle might be used to treat inner ear disorders and 
that future studies on patients are of great clinical interest. 
66
POPULÄRVETENSKAPLIG 
SAMMANFATTNING
Hörselsjukdom är en av de tio vanligaste sjukdomarna i mellan- och 
höginkomstländer med cirka 250 miljoner drabbade människor 
världen över. Under de senaste decennierna har forskningen lett till 
betydande framsteg genom att på cellnivå förklara bakomliggande 
mekanismer till innerörats sjukdomar. En av de stora utmaningarna 
vid läkemedelsbehandling av inneröronsjukdom är innerörats 
otillgänglighet för läkemedel på grund av olika barriärsystem 
som hindrar upptag av läkemedel. Dessutom är innerörat 
svåråtkomligt för en direkt tillförsel av läkemedel eftersom det 
sitter i skallbasen. Nya tekniker för att leverera läkemedel till 
innerörat på ett effektivt och säkert sätt skulle vara av stort värde 
för behandling av patienter med inneröronsjukdom. Genom 
att ge läkemedel lokalt till innerörat i stället för en behandling 
med tabletter eller läkemedelsinjektion till blodet skulle man 
kunna undvika vissa problem såsom läkemedelsbiverkningar 
och läkemedelsinteraktioner och sannolikt även kunna öka 
koncentrationen av läkemedlet i innerörat. 
Målet i avhandlingen har varit att utveckla en metod för 
lokalbehandling av innerörat. Metoden bygger på injektion 
till mellanörat av ett bärarmaterial laddat med läkemedel för 
transport av läkemedlet till den närbelägna hörselsnäckan i 
innerörat.
Hörselsnäckans runda fönstermembran är troligen den 
huvudsakliga transportvägen för läkemedel till innerörat när 
det ges genom en injektion till mellanörat. I avhandlingens 
första studie (artikel I) undersöktes spindelapors runda fönster 
i mikroskop och förekomsten av ett lokalt immunförsvar 
kunde påvisas. En körtelliknande struktur som tidigare inte är 
beskriven i litteraturen identifierades i bindväven invid runda 
fönstermembranets infäste i hörselsnäckans benkapsel. Dessa fynd 
skulle kunna förklara varför det är så ovanligt med infektioner i 
innerörat trots att det är beläget så nära det infektionsbenägna 
mellanörat. Det är också högst troligt att ett lokalt immunförsvar 
i runda fönstret påverkar transporten av läkemedel från mellanöra 
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till inneröra varför detta måste beaktas vid utvecklingen av lokala 
behandlingsmetoder med injektion till mellanörat.
I den andra studien i avhandlingen (artikel II) undersöktes 
tre olika geler som skulle kunna användas som bärarmaterial vid 
läkemedelsadministration till mellanörat. Resultaten talar till 
fördel för gelen hyaluronsyra (HYA-gel) som till skillnad mot 
de två andra gelerna carboxymetyl cellulosa och poloxamer 407 
inte orsakade någon signifikant hörselnedsättning efter injektion 
till mellanörat på marsvin. En undersökning av hur länge gelerna 
stannade kvar i mellanörat liksom mikroskopisk undersökning av 
deras påverkan på mellan- och inneröra stödjer uppfattningen att 
HYA-gelen är den mest effektiva som bärarmaterial för injektion 
till mellanörat.
En viktig faktor för lokal behandling av innerörat genom 
injektion av läkemedel till mellanörat är att bärarmaterialet för 
läkemedlet kommer i kontakt med runda fönstermembranet. Med 
hjälp av magnetkamera undersöktes hur HYA-gelen fördelade 
sig i mellanörat på marsvin efter mellanöreinjektion liksom hur 
länge den kvarstannade (artikel III). HYA-gelen fördelade sig på 
ett förutsägbart sätt, fyllde upp mellanörat väl och stannade kvar 
invid runda fönstret under mer än 24 timmar. Innan injektion till 
mellanörat gavs gjordes ett litet hål i trumhinnan för att släppa ut 
luft och därmed undvika skada på runda fönstermembranet till 
följd av övertryck.
Hypotesen att högre koncentrationer av ett läkemedel i 
innerörat kan uppnås genom injektion till mellanörat jämfört med 
injektion till blodet undersöktes i de fjärde och femte delarbetena 
(artikel IV och V). Antioxidanten tiosulfat har tidigare identifierats 
som en lovande substans för att skydda mot skada av det för 
innerörat skadliga cytostatikapreparatet cisplatin. Mycket högre 
koncentrationer av tiosulfat i innerörat kunde i studien uppmätas 
efter injektion till mellanörat av substansen i HYA-gel jämfört 
med efter att tiosulfatlösning injicerats i blodet. Blodnivåerna 
av tiosulfat efter injektion till mellanörat var låga vilket bekräftar 
att denna metod för läkemedelsadministration till innerörat inte 
medför någon risk för minskad effekt av cisplatin på den tumör 
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man avser att behandla.
I den sista studien (artikel V) visades att en injektion av 
tiosulfatinnehållande HYA-gel till mellanörat på marsvin skyddar 
innerörat från cisplatinorsakad skada. Tiosulfatinnehållande HYA-
gel injicerades till mellanörat tre timmar innan marsvinen erhöll en 
injektion med cisplatin i blodet. Detta bekräftar hypotesen att den 
utvecklade injektionsmetoden med HYA-gel som bärarsubstans 
för läkemedel kan användas för att behandla vissa typer av 
inneröronsjukdom och skada. De experimentella resultaten talar 
för att metoden skulle kunna användas på patienter.
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